Can a new drug help myasthenia gravis patients ditch steroids?

NCT ID NCT07221838

Recruiting now Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether the drug ravulizumab can help people with generalized myasthenia gravis (gMG) safely reduce or stop taking oral steroids. About 75 adults who are already on ravulizumab and taking at least 7.5 mg of prednisone daily will follow a gradual steroid-tapering schedule. The goal is to see if they can lower their steroid dose to 5 mg or less per day—or stop entirely—without their muscle weakness getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab (intravenous) and prednisone/prednisolone (oral corticosteroid)
What this could lead to: If successful, this study could show that ravulizumab allows many patients with generalized myasthenia gravis to safely reduce or stop long-term steroid use, lowering side effects.
What could go wrong: This is a small, single-arm study (no placebo group), so results may not prove cause and effect. Steroid tapering may not work for everyone, and some patients might experience symptom worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS GMG

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Chicago, Illinois, 60637, United States
Research Site
NOT_YET_RECRUITING

Schaumburg, Illinois, 60173, United States
Research Site
NOT_YET_RECRUITING

Neptune City, New Jersey, 07753, United States
Research Site
RECRUITING

Raleigh, North Carolina, 27607, United States
Research Site
NOT_YET_RECRUITING

Knoxville, Tennessee, 37920, United States
Research Site
NOT_YET_RECRUITING

Bochum, 44789, Germany
Research Site
NOT_YET_RECRUITING

Milan, 20122, Italy
Research Site
NOT_YET_RECRUITING

Naples, 80131, Italy
Research Site
NOT_YET_RECRUITING

Rome, 00189, Italy
Research Site
NOT_YET_RECRUITING

Ibaraki, 305-8576, Japan
Research Site
NOT_YET_RECRUITING

Kitakyushu-shi, 807-8555, Japan
Research Site
NOT_YET_RECRUITING

Kumamoto, 860-8556, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.